The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

Rambam Health Care Campus

Status and phase: Unknown; Phase 3

Conditions: Hypercholesterolemia

Treatments: Drug: Niacin\Laropiprant

Study type: Interventional

Funder types: Other

Identifiers

NCT01071525

Niacin-OS

Details and patient eligibility

About

1. Treatment of Hypercholesterolemic patients with niacin will cause a significant decrease in oxidative stress and a decrease in the atherogenecity in blood samples of the patients.
2. A possible correlation between oxidative stress in hypercholesterolemic patients taking niacin to clinical hypercholesterolemia parameters is possible.
3. Using a novel biomarker will enable a precise detection of the change in the oxidative stress in hypercholesterolemic patients.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Hypercholesterolemia,
• age above eighteen

Exclusion criteria

• Treatment with fibrates,
• Pregnant/Breast feeding women

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

Niacin

Active Comparator group

Description:

Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\\Laropiprant.

Treatment:

Drug: Niacin\Laropiprant

Control

No Intervention group

Description:

Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.

Treatment:

Drug: Niacin\Laropiprant